Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ ...
Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) Follow today's event live09:30 CEST Investor call audio webcastFull details on our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results